PARADIGM: OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa

Study Title: PARADIGM: OlaPArib And RADiotherapy In newly-diagnosed GlioblastoMa

Study Description: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose escalation study.

Study Design: Phase I dose escalation trial followed by a phase II randomised, double blind trial of radiotherapy plus placebo versus radiotherapy plus olaparib.

Trial Status: Open to recruitment

Chief Investigator: Prof Anthony Chalmers, Beatson West of Scotland Cancer Centre, Glasgow

Sponsor: University of Glasgow / Greater Glasgow and Clyde Health Board

Date Opened: 3rd March 2015

Planned Closure Date: Feb 2019

Target Recruitment: 164 patients

Open to New Sites: Yes

Contact Details: Clinical Trials Unit, Glasgow (CTUG)
Lorna Sweeting (Project Manager)
Cancer Research UK Clinical Trials Unit Glasgow
Beatson West of Scotland Cancer Centre
1053 Great Western Road
Glasgow G12 0YN
Tel: 00 44 (0) 141 301 7194
Fax: 00 44 (0) 141 301 7946
E-mail: [email protected]

Investigator Initiation Slides
Pharmacy Initiation Slides

For queries concerning Pharmacovigilance, or the documents to refer to for the clinical management of trial patients or those that are acting as the Reference Safety Information please contact:

The Pharmacovigilance Team email: [email protected] or

Telephone: 0141 211 0352/0203/3567/3968 or 0141 232 2068

Version of NCI Common Terminology Criteria for Adverse Events (CTCAE) being used for the study (if applicable): 4.03

Click here to download the CTCAE